Marine predatory cone snails (genus Conus) with over 500 species represent what is arguably the largest single genus of marine animals alive today. All Conus are venomous and utilize a complex mixture of Conus peptides to capture their preys and for other biological purposes. Each component of Conus peptides selectively targets a specific subtype of ion channels, neurotransmitter receptors or transporters. Owing to their diversity, more than 50,000 distinct active peptides are theoretically estimated in Conus venoms. These diversified toxins are generally categorized into several superfamilies and/or families based on their characteristic arrangements of cysteine residues and pharmacological actions. Some mechanisms underlying the remarkable diversity of Conus peptides have been postulated: the distinctive gene structure, gene duplication and/or allelic selection, genus speciation, and sophisticated expression pattern and posttranslational modification of these peptides. Due to their highly pharmacological potency and target selectivity, Conus peptides have attracted extensive attention with their potentials to be developed as new research tools in neuroscience field and as novel medications in clinic for pain, epilepsy and other neuropathic disorders. Several instructive lessons for our drug development could be also learnt from these neuropharmacological "expertises". Conus peptides comprise a rich resource for neuropharmacologists, and most of them await to be explored.
The Biology of Cone Snails
The predatory cone snails (genus Conus, family Conidae) with over 500 species may comprise the largest single genus of marine animals living today. These species inhabit in tropical reef environments throughout the world. According to their prey preference, cone snails can be classified into three major groups: the piscivorous preying upon fish (e.g., Conus striatus, C. geographus), the molluscivorous eating mollusk (e.g., C. textile, C. pennaceus) and the vermivorous feeding upon polychaete annelids (e.g., C. imperialis, C. vexillum). All cone snails are venomous predators. Owing to the highly toxic peptides stored in their venoms, these predators with locomotory disadvantages can easily immobilize and capture their agile preys, as well as escape from and defend against their predators and possibly deter the competitors. About 30 cases of human envenomation by fish-hunting cone snails have been recorded so far, in some cases fatal.
Conus are excellent 'experts' in neuropharmacology. They generate a variety of toxins in the long convoluted ducts and store them in venom bulbs. Besides these twoand-line fishing' cone snails (e.g., C. purpurascens, C. striatus and C. magus) and 'net-fishing' cone snails (e.g., C. geographus and C. tulipa). These two kinds of strategies were clearly illuminated in the vivid cartoon by Olivera [2] . For C. purpurascens using the 'hook-and-line' strategy to capture fish, two distinct immobilization phases are subsequently elicited: the excitotoxic shock and the neuromuscular block. The former stage takes place instantaneously after venom injection and stuns the fish rapidly, while the latter lags and completely abolishes the muscle action potentials of its prey [2, 3] . The complicated arrays of Conus venom underlying these two distinct phases are under extensive studies.
Classification and Nomenclature of Conus Peptides
Conus species have developed many distinct venoms as a survival strategy for feeding and defense. Their venoms contain a diverse mixture of biologically active peptides, mostly small and structurally constrained. During the 50 million years of evolution, Conus peptides have been optimized to target specific ion channels, cell-surface receptors and transporters with very high affinities and selectivities. Although more than 50,000 unique peptide sequences exist in Conus venom by estimate, these small peptides can be generally classified into two major categories: (1) those in the majority with disulfide bonds, referred to as conotoxins, and (2) those in the minority with a single or no disulfide bond. Furthermore, they may be broadly grouped into several 'superfamilies' and 'families'. Peptides within the same 'superfamily' share a characteristic cysteine arrangement and a highly conserved signal sequence in the precursors, and members within the same 'family' have in common the unique disulfide bonds and pharmacological activity [4] . Based on these principles, Conus peptides discovered up to now have been clustered into eleven superfamilies (Table 1) : A, M, O, P, S, T, I, conopressin, conantokin, contryphan and contulakin. The superfamily may be subdivided into several families with distinct pharmacological activities (indicated within the following brackets): A-superfamily (α-, αA-,κA-, and ρ-conotoxins); M-superfamily (µ-and 
No cysteine ψ-conotoxins); O-superfamily (ω-, κ-, δ-, µO-, and χ-conotoxins); P-superfamily (spastic conotoxins); Ssuperfamily (σ-conotoxin); T-superfamily (τ-and χ-conotoxins) and I-superfamily (excitatory peptides) [4] [5] [6] . Some other superfamilies not assigned thus far include conopressins, conantokins, contryphans and contulakins, and all of them are either linear or with a single disulfide bond and belong to the non-conotoxin category.
As there is a great diversity in peptide superfamilies and families of cone snail toxins, a variety of Conus peptide targets have been identified, including many voltagegated and ligand-gated ion channels, as well as G-proteincoupled receptors [5, 7, 8] . Conotoxins that target voltage-gated ion channels comprise those delaying the inactivation of sodium channels (e.g., δ-conotoxins) as well as the blockers specific for sodium, calcium, pacemaker and potassium channels (e.g., µ-, ω-, χ-and κA-conotoxins, respectively). Included in the Conus peptides targeting ligand-gated ion channels are antagonists of N-methyl-D-aspartate (NMDA) receptor (e.g., conantokins) and serotonin receptor (e.g., σ-conotoxins) as well as competitive and non-competitive antagonists of nicotinic acetylcholine (ACh) receptor (e.g., α-and ψ-conotoxins, respectively). While contulakins and conopressins are the agonists of G-protein-linked receptors of neurotensin and vasopressin, respectively, ρ-conotoxins act as antagonists of G-protein-coupled α1-adrenoceptor. Noteworthily, ω-and δ-conotoxins share the same cysteine arrangement, but their biological targets are different. Conversely, κ-and κA-conotoxins both target K + channels but possess different disulfide patterns. The unique selectivity of Conus peptides for different physiological targets can be attributed to their well-organized bridging structure, loop variability, and spatial arrangement of functional groups in three-dimensional structure. The structure-function relationships of Conus peptides have been comprehensively reviewed recently [9] .
κA-and κ-family conotoxins inhibiting voltage-gated K + channels together with δ-family conotoxins delaying the inactivation of voltage-gated Na + channels elicit the initial stage (excitotoxic shock) of two distinct immobilization phases during Conus prey capture, while the lagging phase (neuromuscular block) characteristic of complete paralysis is ascribed to the synergetic effects of α-, αA-and ψ-conotoxins competitively or non-competitively inhibiting the binding of ACh to the post-synaptic nicotinic receptor at the neuromuscular junction together with ω-conotoxins acting as blockers of presynaptic voltage-gated Ca 2+ channels to inhibit neurotransmitter release and µ-conotoxins like tetrodotoxin directly blocking skeletal muscle voltagegated Na + channels [2, 3] . These two non-overlapping sets of toxins present in the same venom act synergistically to target the pre-and post-synaptic elements of the neuromuscular junction and maximize the probability of cone snails to successively immobilize and capture the prey. Indeed, the former set of conotoxins is referred to as the 'lightning-strike cabal' and the latter as the 'motor cabal'. These two sets of Conus peptides have endowed such slow-moving predator with the talent to capture the agile prey.
The discovery of Conus peptides has been greatly accelerated during the past years due to the introduction of sophisticated and effective technical approaches. Many research groups and companies are extraordinarily interested in these small peptides and intend to explore this rich resource [10, 11] . An increasing number of Conus peptides have been revealed and characterized. Considering different names were often given by different research groups for one peptide, a systematic nomenclature of these active peptides are under urge to ease confusion and bewilderment. Olivera and Cruz have proposed the criterion for systematic classification and unified nomenclature of Conus peptides [4] . In brief, the final name of a conotoxin (e.g., κ-conotoxin PVIIA) with a distinct activity consists of a Greek letter to designate its pharmacological action, followed by a hyphen before the word 'conotoxin', a oneor two-letter code representing the Conus species, a Roman number indicating its Cys pattern, and terminated with a capital letter for a specific peptide variant. The name of one peptide with unknown pharmacological target (e.g., tx9a) only consists of the species code in lower case letter (s), an Arabic number (designating its Cys pattern) and a small letter for a particular peptide variant. For peptides with the same pharmacological activity but with different cystine framework, a capital letter is introduced to follow the Greek letter to designate a different family (e.g., α and αA, κ and κA). Non-conotoxin families with one or no disulfide bond are usually less diverse and found in fewer species, thus, they are given a name followed by the species code in capital letter (e.g., conopressin-S, contryphan-R and conantokin-G from C. striatus, C. radiatus and C. geographus, respectively). Larger polypeptides (more than 70 aa) are similarly named (e.g., conodipine-M).
The Basis of Conus Peptide Diversity

Functional diversity of Conus peptides
Conus peptides comprise remarkably diverse classes of pharmacologically active small peptides. It appears apparent that each Conus species has its own distinct repertoire of 50-200 different venom peptides and that the venom peptides from different species are surprisingly divergent in sequence. Thus, more than 50,000 unique peptide sequences lie in over 500 species of predatory cone snails by estimate. Each of these components is believed to have its specific biological target. As mentioned above, the Conus venom constitutes a potent pharmacological cocktail, and three distinct targets of Conus peptides have been identified till now: ion channels, cell-surface receptors and neurotransmitter transporters. Among them, conotoxins targeting ion channels are under the most extensive studies. Many kinds of ion channels playing pivotal roles in the basic physiological and pathological events have successfully found to be targeted by conotoxins, such as potassium, calcium and sodium channels. Indeed, conotoxins exhibit a variety of activities and could modulate ion channels in various modes, such as block, potentiation or inactivation. κ-, κA-and χ-conotoxins selectively inhibit voltage-gated K + channels, while κI-conotoxin BtXA (a systematic name for κ-BtX from C. betulinus recently designated in our laboratory) is reported to be the first unique up-modulator of the calcium-and voltage-gated BK channels [12] . Meanwhile, conotoxins preferentially targeting voltage-gated Na + channels contain µ-, µO-and δ-families, and the former two inhibit the activity, while the latter one delays the inactivation of these channels, respectively [13] . The variety of tissue selectivity is also observed within a given structural class of peptides (i.e. they share a common disulfide-bonded framework). For example, µ-conotoxin GIIIB binds to skeletal muscle sodium channels with a high affinity and selectivity, whereas µ-conotoxin PIIIA is a preferential inhibitor of neuronal sodium channels [14] . In contrast to the peptides blocking tetrodotoxin-sensitive sodium channels (e.g., µ-conotoxin GIIIB), recently characterized µ-conotoxin SmIIIA [15] and SIIIA (unpublished data) in C. stercusmuscarum and C. striatus respectively are potent inhibitors of tetrodotoxin-resistant sodium channels. Notably, although ω-and ε-conotoxins possess different cysteine arrangement, they both target N-type voltage-gated Ca 2+ channels and reduce presynaptic Ca 2+ influx [16] . Besides, several key cell-surface receptors also encountered their antagonists or agonists in Conus venom, that is, conantokins, NMDA receptor antagonists; σ-conotoxins, serotonin receptor antagonists; α-and ψ-conotoxins, competitive and non-competitive antagonists of nicotinic ACh receptors; contulakins, neurotensin-like peptides; conopressins, vasopressin receptor agonists; ρ-conotoxins, antagonists of the G-protein-linked α1-adrenoceptor. Except that, a recently discovered conotoxin family, χ-conotoxins, has been identified to selectively inhibit the activity of neuronal noradrenaline transporter [8] . With the diversity of nicotinic ACh receptor subunits present in the specific prey, individual cone species may produce six or more distinct α-conotoxins and other αA-and ψ-conotoxins, all of which inhibit the postsynaptic nicotinic receptors but in different action modes. Further analysis of α-conotoxin family implies that even in a single Conus species there are several distinct members with similar biological function but selectively aiming at a different subtype of a common target [5, 17] . Such high target specificity and affinity of Conus peptides will offer a broad prospect to discover novel subtypes of the target of interest and to develop potent drugs for the treatment of specific disorders with identified pharmacological targets.
The basic elements for generation of Conus peptide diversity
Over tens of millions of years, the venom components of cone snails have undergone rapid and extraordinary evolution, and exhibit an extreme diversify. The versatile activity and unprecedented target selectivity of Conus peptides stem from their specific disulfide bond framework combined with hyper-variable intercysteine amino acid sequences. Although the exact molecular mechanisms underlining high interspecific divergence are not well clarified, some facts have been firmly established in recent years. Extensive cDNA analysis of Conus peptide precursors elucidates that each Conus peptide is encoded by a single mRNA and processed from a precursor usually between 70 and 120 amino acids in length. The prepropeptide precursor has a distinct structural arrangement: a highly conserved signal sequence at the N-terminus (the 'pre-region'), a rather conserved intervening spacer (the 'pro-region') and the hypervariable mature peptide at the C-terminus. Although the mature sequences from different or even the same species can vary greatly with each other, the signal sequences of Conus peptides within all members of a same superfamily are extremely conservative, and their pro-regions relatively conserved (Fig. 1) .
The conservation of signal peptides and variability of mature Conus peptides are intriguing. This juxtaposition of conserved and hypervariable regions within the same translation product reminds us of the mammalian immune system, where antibodies of particular class have defined conserved segments and hypervariable regions. Whether the same mechanism suits to explain the diversity genera-tion of Conus peptides, is under investigation. Analysis of Conus peptide cDNAs reveals that each mature peptide has its own single copy within the gene, which is not reminiscent of antibody-encoding genes in the mammalian immune system. Up to now, several mechanisms of generating Conus peptide diversity are postulated as follows [18] [19] [20] [21] . The distinctive gene structure The full-length mRNA of Conus peptide is characteristically organized and comprises three segments (encoding signal peptide, pro region and mature peptide, respectively) with untranslational regions at its both termini. The extremely conserved signal sequence is juxtaposed with hyperdivergent mature peptide except the Cys pattern, which has not been found in other systems thus far. Peptide diversification apparently arises by focal hypermutation of the C-terminal toxin-encoding region. Several hypotheses (such as gene recombination, conversion and replication) have been suggested for the molecular basis of focal hypermutation. Recombination between two parental δ-conotoxin genes of C. magus successfully generated a novel δ-conotoxin sequence, which brought about the intraspecies diversity [18] . The mature toxin region may adopt many forms of non-synonymous and synonymous replacements, deletions and additions for its hypermutation. What is particularly noteworthy is that all these mutations are restricted within the intercysteine loops whereas the rigid disulfide structural frameworks of the peptides remain unchanged. Replacement of some critical residues within the loops may result in dramatic changes in the target selectivity of these peptides. For instance, a single amino acid substitution (Ala 10 Leu) of α-conotoxin PnIA could sufficiently alter its selectivity of ACh receptor subtypes by two orders of magnitude [22] . The pro-regions of Conus peptides, rather conserved, may play important roles in the post-translational modification and the secretion of their mature toxins, whilst the extremely conserved signal sequence may be optimally devised to guide the precursors to specific cell compartment for particular post-translational modification as well as to correctly sort their mature peptides within the cells. In the case of the hydrophobic conotoxin TxVI, its secretion was strongly dependent on its propeptide domain which facilitated the export of this toxin from the endoplasmic reticulum by hitchhiking on sorting receptors [23] . Besides, within the signal region of Conus peptide precursor one or two cysteine residues often exist, and these Cys residues was conjectured to have a sequestration role, i.e., to avoid premature or inappropriate disulfide bond formation in the mature toxin region [2, 4] . Further characterization of their genome structure may also aid the explanation of the molecular mechanism of Conus peptide divergence. Olivera et al. [24] documented that the different small exons encoding three segments of Conus peptide precursor are separated from each other by relatively large introns. Such charac-teristic exon/intron arrangement makes it possible to yield the accelerated evolution of the C-terminal part and the high conservation of its N-terminal part of the precursor through modulation of gene replication or recombination. The gene duplication and allelic selection Duba and Palumbi [25, 26] sequenced a great number of four-loop conotoxin mRNAs from C. ebraeus, C. abbreviatus and C. lividus. Their results suggested that the gene duplication and allelic selection brought about the diversity of Conus peptides possibly linked to ecological diversification and evolutionary success of this genus. Though these three species are all vermivorous and the former two closely related, the mechanisms of their allelic selections are rather Conus peptides may be the most sophisticated in the kingdom of animals as some of these modifications are not described outside the Conus species. Table 2 listed the post-translational modification forms found in Conus peptides to date. Beyond these extremely complicated modifications, some other uncommon phenomena are observed in Conus species. For example, κI-conotoxin BtXA exhibits a proregion downstream of the C-terminus of its mature toxin instead of the common arrangement of pre-pro-mature peptide [12] . Notably, the post-translational modifications of Conus peptides are significant for their biological activities [7, 27, 28] . For example, the first reported glycopeptide isolated from Conus venom, κA-conotoxin SIVA, was characterized from C. striatus [27] , and the second one, contulakin-G, was from C. geographus with a disaccharide attached to its Thr residue at position 10 [28] . In vivo studies demonstrated that the biological potencies of these native glycosylated peptides were significantly greater than those of the synthetic nonglycosylated analogues [20, 27, 28] . Such rich array of post-translational modifications may provide another overlying level of Conus peptide diversity. Presumably, all these modifications require both specific enzymes and their recognition signal sequences (or alternatively characteristic structural features) of cone snails. Although little is known about the molecular mechanisms of most of these post-translational modifications, some unique sequence elements within conopeptide precursors and specialized Conus cellular components involved in (or responsible for) these processes have been clearly identified [29] [30] [31] . In conantokin-G where five of the six glutamic acid residues are χ-carboxylated, the -1 to -20 sequence of its precursor pro-region acts as a recognition signal and greatly enhances the affinity for the vitamin Kdependent χ-glutamate carboxylase. In another aspect, the pro-region of hydrophobic conotoxin TxVI exhibits a role in the accurate sorting and secretion of this peptide [23] . Table 2 Post-translational modifications of Conus peptides Particularly intriguing, Dutton et al. [21] recently reported that the synthetic α-conotoxin AuIB with non-native disulfide bond surprisingly had approximately ten times greater potency than the native peptide. Thus, the disulfide bond isomerization may present a new level of Conus peptide diversity. The rapid diversification of Conus peptides could be regarded as an optimum evolutionary strategy responsible for the rapid change of their preys, predators and competitors. Cone snails may have acquired their complex venoms over the last 50 million years and generated more and more effective toxins for targeting the key components of the nervous system of their preys. The successive extreme changes in climate and/or geological catastrophe may select for Conus peptide hypermutation and may be the key factor in the species richness of the genus Conus. With the evolutionary advantage of rapidly optimizing new sets of peptides after geological changes, Conus could quickly adapt to a new ecological context. In a historical view, cone snails have utilized a combinatorial library strategy to evolve new peptides in their venoms for survival through successive rounds of strong selection.
Basic Research and Therapeutic Applications
Marine cone snails have successfully evolved to contain a superstore of bioactive small peptides. Over millions of years of evolutionary selection, an incredibly source of these peptides has been developed to target specific ion channels, cell-surface receptors and transporters with extremely high affinities and selectivities. Owing to their high potency and exquisite selectivity, Conus peptides are widely used as research tools in the fields of neuroscience and pharmacology, and several conopeptides are at various stages of clinical trials for treatment of a variety of human diseases (Table 3) [10, 32] . Since 1996, a large number of patents have been approved for Conus peptides and their derivatives.
Targeting ion channels
As discussed above, Conus peptides exhibit a rich array of components targeting various kinds of ion channels. The ω-conotoxin family composed of small peptides with 24-31 amino acids in length are constrained to form a rigid conformation cross-linked with three disulfide bonds by incorporating the inhibitor cystine knot (ICK) motif [33] . By virtue of their high affinity and selectivity for different kinds of voltage-gated Ca 2+ channels (VGCCs), ω-conotoxins are widely employed as probes to discriminate the Ca 2+ channel subtypes. ω-conotoxin MVIIC and MVIID from C. magus could preferentially block the N and P/Q-type VGCCs, whereas ω-conotoxin MVIIA and GVIIA exclusively target the N-type. Meanwhile, Fainzilber et al. [34] isolated a novel Conus peptide, ω-conotoxin TxVII, which specifically blocked the L-type VGCCs. Considering the N-type channels mediate Ca 2+ influx at nerve terminals and regulate neurotransmitter release, ω-conotoxins blocking specific presynaptic Ca 2+ channels may have a potential in pain and stroke treatment. For example, ω-conotoxin MVIIA (its synthetic form, Ziconotide), a neuro-specific N-type Ca 2+ channel blocker with an analgesic and neuroprotective potential, is under development by Elan Pharmaceuticals [35] . In the midst of the blockers of other channels, µ-conotoxins like tetrodotoxin (TTX) play a pivotal role in defining the subtypes of voltage-gated Na + channels. In fact, µ-conotoxin GIIIA exclusively inhibiting Nav1.4 has been applied to resolve the clockwise domain arrangement of sodium channel [36] . Two recently characterized µ-cono-toxins, SmIIIA [15] and SIIIA (unpublished data), which could specifically block TTX-resistant sodium channels, are noteworthy. Since TTX-resistant sodium channels (e.g., Nav1.8 and Nav1.9) are predominantly expressed in sensory neurons and involved in the nociceptive signal transmission, µ-conotoxin SmIIIA and SIIIA may not only provide novel and useful tools to investigate the functional roles of these 
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Conus peptides that are on preclinical or clinical trials channels but also have a potential to be developed as efficient pain-killers. Promising in another regard are κ-conotoxins which block potassium channels and might have a wide potential in hypertension, arrhy-thmia or asthma treatment [10] . Nevertheless, a great number of Conus peptides with high selectivity to different targets are still remaining to be exploited as pharmacological tools and/or therapeutic agents.
Targeting neurotransmitter receptors and transporters
Cell membrane receptors mediate versatile signal transductions and play crucial roles in physiological and pathological events. By far, cone snails have optimally designed several sets of Conus toxins targeting multiple kinds of these receptors. α-conotoxin, the first chemically characterized peptide in Conus venom research, is a competitive antagonist of ACh receptor (AChR). This family could not only selectively block nicotinic ACh receptor (nAChR), but also clearly discriminate between muscular and neuronal subclasses of these receptors. In particular, α-conotoxin MII promises to be a useful tool in the study of neuronal β3 subunit-containing AChR [37] . Another α-conotoxin ACV1 (or Vc1.1), recently identified from C. victoriae, has attracted considerable attention. In addition to acting as a neuronal-type nAChR antagonist, this novel α-conotoxin can also suppress the vascular responses to unmyelinated sensory nerve C-fiber activation in rats [38] . ACV1 seems to have more potent, non-addictive and longlasting effects over morphine and does not cause the side effects observed in other pain-killers. Impressively, this peptide can also accelerate tissue repair in the damaged nerves--a unique property not documented yet for any other analgesic agent [39] . Another example of promising antagonist from Conus venom is conantokin which is rich in Gla (χ-carboxylglutamic acid) residues and can selectively antagonize the NMDA receptor [40] . These ionotropic glutamate receptors ensure acceleration of Ca 2+ influx and play critical roles in the pathological events such as CNS trauma, epilepsy, pain and the neuronal cell damage caused by acute brain ischemia. Thus, antagonists of NMDA receptors possess a considerable potential for CNS disorder therapies. For instance, conantokin-G (its synthetic form, CGX-1007), the first identified peptide competitively antagonizing NR2B-containing subtype of NMDA receptors with high selectivity and affinity [41] , has exhibited a significant neuroprotective effect in rat models of ischemia and is under development as an antiepileptic agent by Cognetix and Medtronic. At the present time, the NMDA receptor-targeting drugs prescribed in clinic are devoid of selectivity and often evoke unfavorable side effects. As conantokins are capable of selectively targeting different subtypes of NMDA receptors, they could meet specific therapeutic needs with a reduced likelihood of side effects [42] . Also in the case of 5-hydroxytryptamine (5-HT) receptor, no pharmacological probe capable of selectively discrimi-nating among multiple subtypes of this receptor has been found thus far. Fortunately, σ-conotoxin GVIIIA, a novel Conus peptide purified from C. geographus, can competitively antagonize the 5-HT 3 subtype receptor with high specificity (5-HT 3 receptor is the unique ligand-gated ion channel subtype of the serotonergic receptor family consisting of at least 14 subtypes) [7] . Antagonists of 5-HT 3 receptor have potential antiemetic activity, and may be exploited to minimize chemotherapy-induced nausea and vomiting in clinic. Meanwhile, two new classes of Conus peptides specifically blocking α 1 -adrenoceptors (ρ-conotoxin TIA) and nor-adrenaline transporters (χ-conotoxin MrIA) were recently characterized from C. tulipa and C. marmoreus, respectively. Because these peptides exhibit greater selectivity than the current drugs used in clinic, they could also lead to the development of improved therapeutics [8, 43] .
Pharmacological strategy of cone snails
The venoms of cone snails are a natural resource of peptides with a promising pharmaceutical potential for developing drugs that target ion channels, cell-surface neurotransmitter receptors and transporters. During 50 million years of evolution, cone snails have turned to be expertises in neuropharmacology. Some instructive lessons could be learnt from cone snails for our modern drug design [44] . Small compounds stable and water-soluble Most of Conus peptides are small with around 20 residues in length that makes large scale production of their synthetic forms feasible and easy. By comparison, both α-conotoxin ImI and α-bungarotoxin are potent nAChR antagonists, while the former (12 aa) is much smaller than the latter (74 aa). Furthermore, most Conus peptides are highly water-soluble and stable, meeting the essential requirement for pharmaceutics. Stiff framework of the molecule Although Conus peptides are mostly small-sized and strikingly hypermutated, their conformations in solution are invariably constrained. Such structural rigidity of these peptides is conferred by the stiff framework constructed upon the highly conserved Cys residues. Even in the case of conantokins which lack disulfide bond, an α-helical conformation is adopted through the intramolecular Gla residues chelated with Nov., 2004 [45] . It was hypothesized that the common constrained framework endowed these peptides with the activity to target the same 'macrosite', while the hypermutated sequences within the intercystine loops might contribute to their extreme preference and binding affinity for different 'microsite' [46] . In fact, focal modifications of lead compounds can generate drugs with a high selectivity and less side effects. Synergy of operations Cone snails take advantage of the synergetic effects of different Conus peptides aiming at various targets to capture their preys efficiently. Two distinct phases of their prey capture are elicited by different sets of Conus peptides (e.g., 'lightning-strike cabal' and 'motor cabal'). Such strategy of synergy has been adopted in the treatment of diseases (i.e. different kinds of drugs with different pharmacological efficiencies are often under combined administration in clinic).
Future Prospects
Conus peptides comprise a vast array of active peptides with over 50,000 estimated components. Given that only 0.2% of this library was published in the scientific literature, most of this 'arsenal' remain to be explored. In the retrospect of Conus venom research, Craig Clark of the University of Utah inspiringly injected venom fractions directly into the central nervous system of mammals, instead of using the standard intraperitoneal injection. Intracranial injection of Conus venom fractions in mice elicited the amazing array of different behavioral phenotypes revealing the true pharmacological diversity of Conus venoms [4, 47] . With this recording of many diverse symptoms elicited in mice, several Conus peptides were successfully characterized from C. geographus, such as a 'shaker' peptide (ω-conotoxin GVIA), 'scratcher' peptide (conopressin-G), 'sleeper'peptide (conantokin-G) and 'sluggish' peptide (contulakin-G). Today, with rapid development of effective methodology and sensitive bioassay, many novel Conus active peptides have been characterized not only by chemical but also by molecular biological approaches. Indeed, a great number of novel Conus peptides have been discovered over these years by means of cDNA cloning [38] . Meanwhile, the extensive structure-function studies of these diverse peptides with various pharmacological potential and target selectivity are underway, and will provide a substantial basis to understand the mechanisms of the 'ligand-receptor' interactions and for the development of new probes and therapeutic agents [9, 48] . With the novel ion channels and cell-surface receptors/transporters (especially G-protein coupled receptors) rapidly discovered, their putative 'exogenous ligands' present in the venoms of cone snails will accelerate the understanding of the fundamental roles of these elements in physiology and disease. Furthermore, a given structural framework of Conus peptides already proved to target certain subtype of receptor or ion channel might serve as an excellent template for the development of novel therapeutics with higher selectivity and less side effects in pharmaceutical industry.
Several postulates have been presented to explain the generation of conotoxin diversity [18] [19] [20] [21] . In future, extensive analysis of the cone snail genes (sequence and structure characteristics of their mRNAs and genome) may provide a fundamental basis to elucidate the mechanisms of Conus peptide biosynthesis and diversity. Their complicated post-translational modifications, one extremely sophisticated issue, also remain to be clarified. Though some progresses have been made in these aspects, massive efforts should be laid on the biological exploration of these rich pharmaceutical resources. 
